The CMPSR continues to provide a resource for high quality collection and analysis of pharmacokinetic specimens. However, the CMPSR has greatly expanded to include collection, processing and analysis of clinical specimens for translational/correlative and pharmacodynamic studies associated with the Center's clinical trials program. Additional objectives of the CMPSR are to: 1) Provide a resource for high-quality collection, processing and analysis of clinical specimens for pharmacokinetic and correlative studies;2) Develop translational components for investigator-initiated clinical trials;and 3) Identify and validate biomarkers and molecular signatures that are predictive of response to therapy and investigate drug activity, pharmacodynamic responses and mechanisms of acquired or innate resistance. Further, the CMPSR provides UC Davis clinical investigators a comprehensive resource for clinical trial protocol development, including standardized and/or trial-specific language for specimen collection, and development of correlative study scientific components. It also provides services for preclinical modeling and biologic investigations of novel agents and therapeutic combinations that can serve as rationale for study development. Resource personnel work closely with the CTSU and clinical trial investigators to incorporate comprehensive and meaningful correlative and pharmacokinetic components into each trial. Users of the CMPSR are primarily UC Davis Cancer Center clinical investigators developing clinical trials. The CMPSR involvement in a clinical trial may range from the collection and shipping of UCD patient blood specimens enrolled on a cooperative group study, to broader roles including development and implementation of specialized specimen collection procedures and novel assays, comprehensive molecular correlative analysis of trial specimens and preclinical in vitro or in vivo modeling to generate drug mechanism hypotheses that can be tested in the clinic. These efforts often include significant CMPSR input during trial protocol development. The CMPSR also services as a bridge between clinical investigators with other Shared Resources.

Public Health Relevance

This resource handles biological specimens used to understand how cancer therapies work, how cancers can be detected, how the body processes drugs, and how various combinations of therapies can be more or less effective. The specimens and analytical studies are carried out in conjunction, for the most part, with cancer clinical trials. Its results are important to improving options for treating different types of cancers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA093373-12
Application #
8743648
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
12
Fiscal Year
2014
Total Cost
$152,393
Indirect Cost
$53,106
Name
University of California Davis
Department
Type
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Zeng, Shu-Xiong; Zhu, Yanjun; Ma, Ai-Hong et al. (2017) The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer. Clin Cancer Res 23:6580-6591
Zhong, Cheng; Han, Ju; Borowsky, Alexander et al. (2017) When machine vision meets histology: A comparative evaluation of model architecture for classification of histology sections. Med Image Anal 35:530-543
Gingrich, Alicia A; Elias, Alexandra; Michael Lee, Chia-Yuan et al. (2017) Predictors of residual disease after unplanned excision of soft tissue sarcomas. J Surg Res 208:26-32
Li, Tianhong; Piperdi, Bilal; Walsh, William V et al. (2017) Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung Cancer. Clin Lung Cancer 18:60-67
York, D; Sproul, C D; Chikere, N et al. (2017) Expression and targeting of transcription factor ATF5 in dog gliomas. Vet Comp Oncol :
Yap, Stanley A; Yuh, Lindsay M; Evans, Christopher P et al. (2017) Evolving patterns of care in the management of stage I non-seminomatous germ cell tumors: data from the California Cancer Registry. World J Urol 35:277-283
(2017) New and emerging developments in extensive-stage small cell lung cancer therapeutics: Erratum. Curr Opin Oncol 29:88
Johnson, Lianna M; Du, Jiamu; Hale, Christopher J et al. (2017) Corrigendum: SRA- and SET-domain-containing proteins link RNA polymerase V occupancy to DNA methylation. Nature 543:136
Jian, Chao; Tu, Mei-Juan; Ho, Pui Yan et al. (2017) Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models. Oncotarget 8:30742-30755
Wan, Debin; Yang, Jun; Barnych, Bogdan et al. (2017) A new sensitive LC/MS/MS analysis of vitamin D metabolites using a click derivatization reagent, 2-nitrosopyridine. J Lipid Res 58:798-808

Showing the most recent 10 out of 733 publications